| [1] |
师金，梁迪，李道娟，等．全球女性乳腺癌流行情况研究[J]．中国肿瘤，2017，26(9):683-690.
|
| [2] |
Winn AN, Dusetzina SB. The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer[J]. Pharmacoepidemiol Drug Saf, 2016，25(8): 953-959.
|
| [3] |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer, version 3.2019 [EB/OL]. [2019-09-06].
URL
|
| [4] |
中国抗癌协会乳腺癌专业委员会．中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J]．中国癌症杂志，2017，27(9):695-760.
|
| [5] |
McCowan C, Wang S, Thompson AM，et al. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study[J]. Brit J Cancer, 2013，109(5): 1172-1180.
|
| [6] |
Wuensch P, Hahne A, Haidinger R, et al. Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor？[J]. J Cancer Res Clin, 2015，141(1): 55-60.
|
| [7] |
Font R, Espinas JA, Gil-Gil M，et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain[J]. Br J Cancer, 2012，107(8): 1249-1256.
|
| [8] |
Joyce AC, Anuja R, Anita B, et al. Medication compliance and persistence: terminology and definitions[J]. Value Health, 2008，11(1): 44-47.
|
| [9] |
Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy[J]. Crit Rev in Oncol Hemat, 2010，73(2): 156-166.
|
| [10] |
Ziller V, Kalder M, Albert US, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer[J]. Ann Oncol, 2008，20(3):431-436.
|
| [11] |
Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia[J]. Pharmacoeconomics, 2007，25(6): 481-496.
|
| [12] |
Ali EE, Cheung KL, Lee CP, et al. Prevalence and determinants of adherence to oral adjuvant endocrine therapy among breast cancer patients in Singapore[J]. Asia Pac J Oncol Nurs, 2017, 4(4): 283-289.
|
| [13] |
Calip GS, Xing S, Jun DH, et al. Polypharmacy and adherence to adjuvant endocrine therapy for breast cancer[J]. J Oncol Pract, 2017，13(5): e451-e462.
|
| [14] |
Farias AJ, Du XL. Association between out-of-pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among medicare patients with breast cancer[J]. J Clin Oncol, 2017，35(1):86-95.
|
| [15] |
Morisky DE, Ang A, Krousel-wood M, et al.Predictive validity of medication adherence measure in an out-patient setting[J]. J Clin Hypertens (Greenwich), 2008，10(5):348-354.
|
| [16] |
Kemp A, Preen DB, Saunders C, et al. Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice? [J]. Springerplus, 2014, 3:282.
|
| [17] |
Güth U, Myrick ME, Kilic N, et al. Compliance and persistence of endocrine adjuvant breast cancer therapy[J]. Breast Cancer Res Treat, 2012，131(2): 491-499.
|
| [18] |
朱叶卉，黄嘉玲，胡雁，等．乳腺癌患者内分泌治疗的服药依从性研究[J]．护理学杂志，2013，28(16):43-45.
|
| [19] |
宋涛．绝经前乳腺癌患者内分泌治疗依从性的调查和影响因素分析[D]. 石家庄：河北医科大学，2017.
|
| [20] |
王旭．绝经后乳腺癌患者内分泌治疗依从性研究[D]．河北：河北医科大学，2017.
|
| [21] |
中国乳腺癌内分泌治疗专家共识专家组．中国乳腺癌内分泌治疗专家共识(2015年版)[J]. 中国癌症杂志，2015，25(9):755-760.
|
| [22] |
Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer[J]. J Clin Oncol, 2003，21(4): 602-606.
|
| [23] |
张菊，张文会，徐林燕，等．乳腺癌内分泌治疗患者服药信念现状及影响因素分析[J]．护理学杂志，2016，31(20):18-21.
|
| [24] |
Stanton AL, Petrie KJ, Partridge AH. Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry[J]. Breast Cancer Res Treat, 2014，145(2): 525-534.
|
| [25] |
郭繁，褚旭英，高晋南．乳腺癌内分泌治疗的依从性研究[J]．山西职工医学院学报，2011，21(2):26-28.
|
| [26] |
Riley GF, Warren JL, Harlan LC, et al. Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D[J]. Medicare Medicaid Res Rev, 2011，1(4):001.04.a04.
|
| [27] |
Livaudais JC, Hershman DL, Habel L, et al. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor positive breast cancer[J]. Breast Cancer Res Treat, 2012，131(2):607-617.
|
| [28] |
Kimmick G, Anderson R, Camacho F, et al. Adjuvant hormonal therapy use among insured, low-income women with breast cancer[J]. J Clin Oncol, 2009，27(21):3445-3451.
|
| [29] |
Livaudais JC, Li C, John EM, et al. Racial and ethnic differences in adjuvant hormonal therapy use[J]. J Womens Health(Larchmt), 2012, 21(9):950-958.
|
| [30] |
吴绍勇，彭星辰，冉启志. Luminal型乳腺癌患者内分泌药物治疗依从性的影响因素分析[J]．中国药房，2018，29(18):2528-2531.
|
| [31] |
Lee JY, Min YH. Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer[J]. BMC Women’s Health, 2018，18(1):48.
|
| [32] |
Simon R, Latreille J, Matte C, et al. Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up[J]. Can J Surg, 2014，57(1): 26-32.
|
| [33] |
Jacob L, Hadji P, Kostev K. Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany[J]. J Geriatr Oncol, 2016, 7(3):169-175.
|
| [34] |
Hadji P, Ziller V, Kyvernitakis J, et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis[J]. Breast Cancer Res Treat, 2013，138(1): 185-191.
|
| [35] |
李振华，肖海静．知信行理论模式在乳腺癌术后出院患者延续护理中的应用[J]．齐鲁护理杂志，2019，25(2):23-25.
|
| [36] |
刘诗盈，王爱平，金锋，等．乳腺癌患者内分泌治疗依从性和服药信念的现状及相关性研究[J]．中国医科大学学报，2017，46(8):698-702.
|
| [37] |
伍麟，车文博，郭增花．应激的多视角解析[J]．健康心理学杂志，2004, 12(1):49-51.
|
| [38] |
Aiello Bowles EJ, Boudreau DM, Chubak J, et al. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer[J]. J Oncol Pract，2012，8(6): e149-e157.
|
| [39] |
Hershman DL, Kushi LH, Hillyer GC, et al. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL)[J]. Breast Cancer Res Treat, 2016，157(1): 133-143.
|
| [40] |
Nabieva N, Fehm T, Häberle L, et al. Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: results of the prospective EvAluate-TM study [J]. Eur J Cancer, 2018，96:82-90.
|
| [41] |
杜玲．接受内分泌治疗的乳腺癌患者服药依从性的影响因素探讨[J]．中外医学研究，2017，15(32):41-42.
|
| [42] |
郭晔，郭广香，隗和红，等．乳腺癌内分泌治疗的依从性研究及影响因素分析[J]．中国民康医学，2014，26(15):33-36.
|
| [43] |
Kroenke CH, Hershman DL, Gomez SL, et al. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system[J]. Breast Cancer Res Treat, 2018，170(3): 623-631.
|
| [44] |
Liu Y, Malin JL, Diamant AL, et al. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication[J]. Breast Cancer Res Treat, 2013，137(3): 829-836.
|
| [45] |
Hadji P, Blettner M, Harbeck N, et al. The patient's anastrozole compliance to therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer[J]. Ann Oncol, 2013，24(6):1505-1512.
|
| [46] |
Heiney SP, Parker PD, Felder TM, et al. A systematic review of interventions to improve adherence to endocrine therapy[J]. Breast Cancer Res Treat, 2019，173(3):499-510.
|
| [47] |
宋淑芬，佘晓佳，秦期，等．应用个案管理模式提高乳腺癌患者内分泌治疗的依从性[J]．护理学报，2011，18(18):24-26.
|